These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 96888)
21. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs]. Bolpe J; de Lapenta DF; García-Carrillo C Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392 [TBL] [Abstract][Full Text] [Related]
22. A potency assay for brucella allergens in guinea pigs. Jones LM Dev Biol Stand; 1976; 31():165-70. PubMed ID: 1261735 [TBL] [Abstract][Full Text] [Related]
23. [Use of a phenol-soluble Brucella antigen in man as a test to detect specific skin sensitivity]. Bertrand A; Bentejac MC; Biron G; Siffert M; Bostvironnois C; Roumiantzeff M Dev Biol Stand; 1984; 56():547-51. PubMed ID: 6436112 [No Abstract] [Full Text] [Related]
24. Properties of an immunogenic fraction from Brucella abortus 45/20. Corbel MJ; Redwood DW Dev Biol Stand; 1984; 56():159-68. PubMed ID: 6436092 [TBL] [Abstract][Full Text] [Related]
25. Leukocyte migration inhibition by a specific antigen in human brucellosis. Nyerges G; Telegdy L Infection; 1975; 3(4):213-6. PubMed ID: 812829 [TBL] [Abstract][Full Text] [Related]
26. [Experimental study of the allergic properties of tomicide. The allergic properties of the native preparation]. Blinkova LP; Efremova VN Antibiotiki; 1980 Jul; 25(7):528-31. PubMed ID: 7406465 [TBL] [Abstract][Full Text] [Related]
27. Late asthmatic reactions to inhalation of fractions from extracts of Candida albicans and Asperguillus fumigatus. Kabe J Allerg Immunol (Leipz); 1974-1975; 20-21(4):393-401. PubMed ID: 4283487 [TBL] [Abstract][Full Text] [Related]
28. Clinical and histological features of brucellin skin test responses in Brucella suis biovar 2 infected pigs. Dieste-Pérez L; Barberán M; Muñoz PM; Moriyón I; Blasco JM Vet Immunol Immunopathol; 2015 Jan; 163(1-2):77-85. PubMed ID: 25480681 [TBL] [Abstract][Full Text] [Related]
29. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155 [TBL] [Abstract][Full Text] [Related]
30. [Current advances in the biochemistry and biological properties of Brucella antigens]. Dubray G Dev Biol Stand; 1984; 56():131-50. PubMed ID: 6436090 [No Abstract] [Full Text] [Related]
31. Immunoproteomic characterization of Brucella abortus 1119-3 preparations used for the serodiagnosis of Brucella infections. Al Dahouk S; Nöckler K; Scholz HC; Tomaso H; Bogumil R; Neubauer H J Immunol Methods; 2006 Feb; 309(1-2):34-47. PubMed ID: 16427071 [TBL] [Abstract][Full Text] [Related]
32. Antibody response, delayed hypersensitivity, and immunity in guinea pigs induced by smooth and rough strains of Brucella abortus. Jones LM; Berman DT J Infect Dis; 1971 Jul; 124(1):47-57. PubMed ID: 5004116 [No Abstract] [Full Text] [Related]
33. The adjuvant activity of mycobacterial RNA preparations and synthetic polynucleotides for induction of delayed hypersensitivity to purified protein derivative in guinea pigs. Casavant CH; Youmans GP J Immunol; 1975 Mar; 114(3):1014-22. PubMed ID: 803534 [TBL] [Abstract][Full Text] [Related]
34. [Allergic diagnosis of bovine brucellosis. 1. Conditions for the use of a purified protein allergen: brucellin (author's transl)]. Fensterbank R; Pardon P Ann Rech Vet; 1977; 8(2):187-93. PubMed ID: 413466 [TBL] [Abstract][Full Text] [Related]
35. [Biological control of the brucellin INRA in sensitized guinea pigs: a guide for the statistical analysis of results]. de Reviers M; Fensterbank R Ann Rech Vet; 1984; 15(3):395-403. PubMed ID: 6517480 [TBL] [Abstract][Full Text] [Related]
36. [A model of immediate sensitization to brucellosis antigen]. Sukhodoeva GS; Beklemishev ND; Bul'vakhter IaL Zh Mikrobiol Epidemiol Immunobiol; 1972 Feb; 49(2):127-31. PubMed ID: 4623772 [No Abstract] [Full Text] [Related]
37. Differentiation of mycobacteria by "in vivo" and "in vitro" delayed hypersensitivity reactions. Filho PO; Beam RE; Sud MA; Selin MJ; David HL Rev Bras Pesqui Med Biol; 1978 Jun; 11(2-3):111-5. PubMed ID: 98814 [TBL] [Abstract][Full Text] [Related]
38. Use of synthetic peptides corresponding to sequences of Mycobacterium leprae proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Estrada IC; Gutiérrez MC; Esparza J; Quesada-Pascual F; Estrada-Parra S; Possani LD Int J Lepr Other Mycobact Dis; 1992 Mar; 60(1):18-27. PubMed ID: 1602190 [TBL] [Abstract][Full Text] [Related]
39. Cutaneous basophil anaphylaxis. Immediate vasopermeability increases and anaphylactic degranulation of basophils at delayed hypersensitivity reactions challenged with additional antigen. Askenase PW; Debernardo R; Tauben D; Kashgarian M Immunology; 1978 Nov; 35(5):741-55. PubMed ID: 721140 [TBL] [Abstract][Full Text] [Related]
40. Immunochemical analysis of soluble antigens of Mycobacterium lepraemurium. Kwapinski G; Kwapinski EH Int J Lepr Other Mycobact Dis; 1976; 44(4):443-7. PubMed ID: 66213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]